Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Jan

Today In Oncology

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leader in Global Cancer Care, Paul E. Goss, MD, PhD, Dies at 70

New Report Shows Colorectal Cancer is Now Leading Cancer Death Among Those Under 50

Pembrolizumab Plus Lenvatinib in Recurrent Gynecologic Clear Cell Carcinoma

Cabozantinib and Temozolomide in Unresectable or Metastatic Leiomyosarcoma

Nutrition Muscle Loss Compromises Survival in Patients With Cervical Cancer Undergoing Chemoradiotherapy